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SUMMARY 
 
 
 
Messenger RNA (mRNA) posttranscriptional regulation has been implicated in the 
development and/or progression of several diseases including many types of cancer, 
rheumatoid arthritis, vascular disease, and Alzheimer’s disease.  Differential regulation 
of Androgen Receptor (AR) mRNA has been associated specifically with prostate cancer 
progression.   In this thesis, molecular beacons were developed to allow for the 
detection of the expression and localization of AR mRNA in live prostate cancer cells. 
These beacons were then applied as a tool for studying how AR mRNA regulation is 
involved in prostate cancer growth and advancement.  Two AR mRNA targeted beacons 
were designed and tested in solution and in live cells to determine their functionality.  
The beacon-based approach for AR mRNA detection was then optimized through the 
use of the two beacons in tandem and alteration of their backbone chemistry.  A series 
of validation tests were performed on these beacons, including testing their abilities to: 
1) produce a feasible localization pattern, 2) discriminate between AR positive (AR+) and 
AR negative (AR-) prostate cancer cell lines and 3) follow stimulus-induced changes in 
AR mRNA expression.  Based on these results, a dual chimeric beacon approach was 
selected to determine the role of AR mRNA regulation in two systems that represent 
important stages in prostate cancer growth and progression: 1) hormone stimulation of 
androgen-dependent prostate cancer cells and 2) progression of androgen-dependent 
prostate cancer cells to the androgen-independent state.  Our results suggest that 
changes in AR mRNA expression, organization, and localization may be indicative of 
molecular mechanisms involved in these critical transitions associated with prostate 
cancer progression.  Taken together, this work provides a feasibility study for visualizing 
changes in AR mRNA state as a diagnostic measure for evaluating the aggressiveness 
xiii 
 
of the disease and demonstrates the possible utility of therapeutically targeting AR 
mRNA regulation in order to prevent prostate cancer advancement. 
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CHAPTER 1: INTRODUCTION 
 
Understanding the molecular pathogenesis of prostate cancer progression has become 
exceedingly important due to the limited treatment options available once the disease 
has progressed beyond the early-stage androgen-dependent phase to the advanced 
androgen-independent state.  The research presented in this thesis is concerned with 
the potential role of Androgen Receptor (AR) mRNA posttranscriptional regulation in 
promoting prostate cancer progression.  In order to understand why we are interested in 
investigating this specific disease progression mechanism, it is first necessary to 
understand the role of AR in prostate cancer, the potential for mRNA regulation to be a 
player in disease progression, and specifically how AR mRNA is regulated and how this 
regulation could conceivably push both early-stage disease and lead to the development 
of the androgen-independent disease state.   We used molecular beacon technology to 
track AR mRNA in live prostate cancer cells in order to help elucidate the importance of 
posttranscriptional regulation on the progression of this disease.  Learning more about 
how AR mRNA is regulated in prostate cancer could point to potential therapeutic targets 
as well as diagnostic indicators of disease advancement.  
 
1.1 The Role of Androgen Receptor in Prostate Cancer Progression 
Prostate cancer is the second most common form of cancer and the second leading 
cause of cancer related death for men in the United States.  Early-stage prostate cancer 
is classified as androgen-dependent.  This means that the cancer requires the presence 
of androgens to bind to and activate Androgen Receptor (AR), an intracellular hormone 
receptor present in the prostate gland, in order to for the cells to grow and divide.  These 
early-stage androgen-dependent tumors are either surgically removed or treated with 
radiation to destroy the cancer cells.  Tumors that are not eliminated through these 
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methods are often treated with androgen ablation therapy.  In the absence of androgens, 
these tumors will regress.  However, this treatment is often unsuccessful in the long term 
due to the progression of the cancer to the more aggressive androgen-independent 
form.  (1) 
 
AR activity is crucial throughout the course of prostate cancer.  AR is activated when 
dihydrotestosterone (DHT), the reduced form of testosterone, binds to the receptor, 
leading to receptor dimerization, translocation to the nucleus, and binding of the AR 
dimer to Androgen Response Element (ARE) sequences in the promoter regions of 
target genes, altering their expression.  Target genes include cell proliferation genes 
such as Cyclin dependent kinases (CDKs), Cyclins, growth factors, cell survival genes 
that suppress apoptosis, Prostate Specific Antigen (PSA), and AR itself.  Therefore, 
increased AR activity and subsequent regulation of these target genes leads to 
increased cell division and decreased apoptosis.   (1) 
 
As stated earlier, early-stage prostate cancer is dependent on the presence of 
androgens, mainly DHT, to activate AR.  When prostate cancer is in this androgen-
dependent state, a common method of treatment is to block AR activity through 
androgen ablation, which can be achieved through surgical or chemical castration.  
Some androgen ablation therapy drugs are 5α-reductase inhibitors such as finasteride 
that work by blocking the conversion of testosterone to DHT.  Other drugs such as 
cyproterone acetate, flutamide, and bicalutamide function as DHT competitors that block 
site accessibility on AR.  (2,3)    However, after period of 1 to 2 years, some prostate 
cancer cells can become resistant to androgen ablation therapy.  (4)  This population of 
cells will continue to grow and divide despite the absence of androgens, transforming the 
cancer into the more aggressive and less treatable androgen-independent form.   
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There are several ways that prostate cancer can transition to androgen-independence.  
One method is to increase the sensitivity of the cells to androgen so that low levels will 
be enough to push the growth pathway.  Prostate cancer cells can achieve 
hypersensitivity to low levels of androgen through AR gene amplification, which in turn 
leads to increased AR protein production.  AR gene amplification is present in about 
one-fifth to one-third of these advanced tumors.   If prostate cancer cells undergo 
mutations that increase 5α-reductase activity, this will lead to increased conversion of 
testosterone to the more active DHT form, which will help push the AR pathway despite 
low levels of androgen.    Mutations that make AR more stable and/or translocate to the 
nucleus more easily will also allow for the receptor to have increased activity even when 
androgen levels are low. (1-6) 
 
A second method by which prostate cancer cells can become androgen-independent is 
through mutations in the AR gene that lowers the specificity of the receptor’s binding 
site.   Decreased specificity of the binding site will allow other molecules besides DHT to 
bind to and activate the receptor.  This becomes increasingly problematic is cases where 
the AR gene is mutated so that the receptor responds to androgen-antagonists such as 
flutamide the same way that the receptor responds to androgens.  When this happens, 
androgen ablation therapy won’t only stop being effective, but it will become a harmful 
factor in promoting prostate cancer growth.  (1-6) 
 
A third method that can lead to this transition is when mutations occur that allow AR to 
be activated in a non-ligand-dependent manner.  AR can be mutated to make it 
constitutively active or mutations may occur that allow for the activation of AR through 
other ligand-independent methods such as phosphorylation.  (1-6) 
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Androgen-independence can also be achieved by bypassing the AR pathway altogether 
through genetic changes that push other growth pathways such as the Bcl-2 pathway.   
This will allow prostate cancer cells to grow in spite of the fact that the dominant AR 
pathway is no longer being pushed.  In the case of AR- prostate cancer, mechanisms 
like these must be employed to allow for cancer cell growth and survival. (1-6)  
 
 While all of these potential mechanisms for pushing prostate cancer into the androgen-
independent phase are important potential therapeutic targets, we are interested 
investigating the mechanism by which prostate cancer cells employ differential AR 
mRNA posttranscriptional regulation in order to circumvent the need for androgen 
stimulation.  (7)  The potential importance of this mechanism will be discussed further in 
section 1.3.   But in order to understand why it is feasible that AR mRNA regulation could 
be critical for prostate cancer progression, it is first important to review other cases 
where posttranscriptional regulation has been implicated as an important player in the 
development and/or progression of disease.  
 
1.2 Posttranscriptional Regulation of mRNA in Disease 
Posttranscriptional regulation of mRNA plays an important role in regulating gene 
expression.  A key way that mRNA is regulated is through the interaction of various 
RNA-binding proteins with cis-elements within the untranslated regions of an mRNA.  
These RNA-binding proteins can affect mRNA localization, stability, and translational 
efficiency.  Changes in mRNA regulation have been associated with many diseases 
including cancer, arthritis, and Alzheimer’s disease.  (8) 
 
Changes in mRNA stability have been a common alteration seen in several diseases.  
Crucial transcription factors such as C-myc, cytokines, and growth factors such as 
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Interleukin-6 (IL-6) often have higher mRNA stability in cancer cells because increased 
production of these proteins will push the cells to grow and divide.  Tumor necrosis 
factor α (TNFα) is often mutated to increase mRNA stability in chronic inflammatory 
arthritis because accumulation of this protein supports this development of the disease.  
(8,9)   A decrease in β adrenergic receptor (β-AR) mRNA stability has been shown to 
accompany low levels of β-ARs seen in patients with hypertension and myocardial 
failure.  (9) 
 
Differential posttranscriptional regulation can be caused by both mutations in protein 
binding sites within an mRNA as well as changes in RNA-binding protein expression.  
Changes in RNA-binding protein expression have been specifically associated with 
cancer development.  For example, amplification of a key RNA-binding protein, coding 
region determinant-binding protein (CRD-BP), which binds to and stabilizes C-myc 
mRNA, has been found in approximately one-third of breast cancers.  HuR is an RNA-
binding protein that has been shown to be upregulated in several tumor types, including 
cancer of the nervous system.  HuR promotes the cytoplasmic localization, stabilization, 
and translational efficiency of several cancer promoting mRNAs such as vascular 
endothelial growth factor (VEGF) and TNFα. (8)  Upregulation of VEGF is particularly 
critical to the angiogenic processes required for tumor metastasis.  In the case of β-AR 
mRNA destabilization previously discussed, this critical change in mRNA stability has 
been associated with the upregulation of a destabilizing RNA-binding protein, adenosine 
uridine-rich element/poly-(U) binding degradation factor 1 (AUF-1). (9) 
 
Mutations in the protein binding elements within various disease-relevant mRNA and 
disease-associated differential expression of critical RNA-binding proteins have both 
become targets for pharmacological intervention. (9,10)  By targeting the mRNA as 
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opposed to the protein it produces, you afford yourself the opportunity to disrupt a 
disease-associated pathway where the protein is inaccessible or highly mutated. (10)  
Since no drugs have been identified so far that can specifically disrupt an RNA-binding 
protein-mRNA interaction, research has turned to interfering with the synthesis and/or 
functional capabilities of these RNA-binding proteins.  Signaling cascades such as the 
mitogen-activated protein kinase (MAPK) and protein kinase C (PKC) pathways regulate 
the expression of various mRNA stabilizing and destabilizing proteins, making them an 
attractive therapeutic target.  (9) 
 
Given the importance of mRNA posttranscriptional regulation in the development and 
progression of several diseases, the ability to visualize and track these critical mRNAs in 
live cells has the potential to be incredibly useful for studying these important biological 
mechanisms.  Molecular beacons, which will be discussed in further detail in section 1.4, 
are probes used for the detection of mRNA in live cells.  This technology could be a 
useful tool for allowing researchers to study mRNA regulation within these disease 
models. (11-13)   
 
 
1.3 Posttranscriptional Regulation of AR mRNA in Prostate Cancer 
 
Some researchers believe that AR mRNA posttranscriptional modifications, specifically 
those modifications affecting mRNA stability, are essential in controlling AR protein 
production in prostate cancer.  RNA-binding proteins such as HuR and poly(C) RNA-
binding proteins (PCBPs) are known to bind to elements within the 3’-untranslated 
region (UTR) of AR mRNA and influence the regulation of this message.  This regulation 
of AR mRNA is thought to play a critical role in allowing for more efficient production and 
distribution of AR protein within the cell, which can push prostate cancer growth without 
the dependence on androgen stimulation.  (7,14,15) 
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AR mRNA posttranscriptional regulation also plays a role in androgen-dependent 
prostate cancer.  While DHT or synthetic androgen stimulation increases AR protein 
levels in androgen-dependent prostate cancer, including the AR+ androgen-dependent 
LNCaP cell line, it illogically causes a decrease in the AR mRNA levels of these cells.  
(16-20)  However, despite this decrease in AR mRNA expression, AR mRNA stability 
increases upon androgen stimulation and it is this increased mRNA stability that is 
thought to be responsible for the increase in AR protein levels.  (7,17,19)  It is also 
speculated that an increase in the cytoplasmic localization of AR mRNA due to HuR 
shuttling of the message and increases in the translational efficiency of the message by 
both HuR and PCBPs might also be partially responsible for the increase in AR protein 
levels.  (7,15)   
 
The regulation of AR mRNA by these RNA-binding proteins has the potential to have 
more significant implications in androgen-independent prostate cancer.  The ability of 
these RNA-binding proteins to enhance AR protein formation and/or cause a more 
optimal distribution of AR protein within the cell can lead to an increase in the activation 
of the AR pathway and promote prostate cancer growth and advancement in an 
androgen-independent manner.  (7)   
 
The potentially significant role of AR mRNA regulation in prostate cancer progression 
makes this yet another potential target for therapeutic intervention in the fight against 
prostate cancer.  (7,15)   Due to the crucial part AR mRNA regulation might play in this 
disease, using molecular beacons to detect and track this mRNA in live cells could be 
incredibly useful in expanding our understanding of the development and progression of 
prostate cancer.  (11-13)   
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1.4 Molecular Beacons for Live Cell mRNA Imaging 
It has just been proposed that posttranscriptional regulation of AR mRNA by RNA-
binding proteins could be responsible for the increased AR protein accumulation, 
subsequent pathway activation, and uncontrolled cell growth in some cases of 
androgen-dependent and androgen-independent prostate cancer. (7)  The visualization 
of AR mRNA level, structure, and localization changes in androgen-dependent prostate 
cancer cells in response to hormonal induction and transition to androgen-independence 
could elucidate the importance of posttranscriptional regulation of this mRNA in 
promoting prostate cancer progression. 
 
Molecular beacons, commonly used technology for real time RT-PCR product detection, 
have been shown to be useful in detecting mRNA in live cells.  Molecular beacons are 
dual-labeled hairpin-structured oligonucleotide probes with a fluorophore at one end and 
a quencher at the other.  The stem region on each side of the sequence complements to 
each other, holding the fluorophore and quencher together to prevent the emission of 
fluorescence and keep the beacon “silent”.  The hybridization domain, or “loop”, is 
designed to be complementary to a specific mRNA target.  When the mRNA target is 
present, the hybridization domain will bind to the target, opening the stem, displacing the 
fluorophore and quencher and allowing for fluorescence to be emitted upon excitation.   
A depiction of beacon structure and the change in conformation due to beacon-target 
binding is depicted in Figure 1.  (21)     
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Figure 1: Schematic of molecular beacon hybridization to target mRNA.  A 
molecular beacon is a dual-labeled hairpin oligonucleotide probe labeled with a reporter 
fluorophore at one end and a fluorescence quencher at the other end.  Hybridization of 
the beacon with it’s target mRNA opens the hairpin and separates the fluorophore from 
the quencher, allowing a fluorescence signal to be emitted.  Site accessibility on the 
target mRNA can be an issue due to the secondary structure of the message and the 
presence of RNA-binding proteins that block sections of the oligonucleotide sequence. 
 
 
 
The idea of the molecular beacon seems straightforward, but complications including 
target accessibility, probe specificity, and detection sensitivity are obstacles that 
researchers face when trying to employ this technology.  Finding accessible sites on the 
target often involves the testing of multiple beacons targeted to different sites on the 
mRNA, which can be labor intensive.  (11)   
 
Enhancing detection sensitivity involves finding methods for increasing the signal-to-
background ratio.  One method that has been used is dual FRET molecular beacons, 
where two molecular beacons are designed to hybridize to neighboring sequences on 
the mRNA.  One molecular beacon has a donor fluorophore, the other an acceptor 
fluorophore, and when the two beacons bind to the target, the donor fluorophore is able 
to excite the acceptor fluorophore.  For live cell imaging, the donor fluorophore is excited 
and emission is collected in the optimal range for the acceptor fluorophore.  Since two 
binding events are required for the acceptor fluorophore to fluoresce, it is less likely that 
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signal seen is from non-specific beacon opening, leading to an enhanced signal-to-
background ratio.  (12,13,22) 
 
Another method for enhancing detection sensitivity is through the alteration of beacon 
backbone chemistry.  Traditional beacons have an entirely DNA backbone.  DNA-RNA 
interactions are not as strong as RNA-RNA interactions, so opening a DNA beacon to 
hybridize to an RNA target would not be as energetically favorably as an RNA beacon 
opening to bind to an RNA target. The switch to using 2’-O-Methyl (2’-O-Me) RNA 
chemistry, at least in the hybridization domain, enhances the thermodynamic favorability 
of beacon binding and the stability of the binding itself, leading to increased signal-to-
background ratios.  (11,23) 
 
Molecular beacons have been used to detect several mRNAs in live cell assays.  In our 
laboratory, live-cell detection of survivin (22,24), K-ras (13,22), GAPDH (13,24), and 
BMP-4 (11) mRNA, as well as the RNA virus Respiratory Syncytial Virus (RSV) (25,26), 
has been achieved.  Live-cell detection of other mRNAs, such as β-actin mRNA (27,28), 
have also been reported in the literature. 
 
1.5 Specific Aims 
It was our goal to use a molecular beacon based approach to track AR mRNA in order to 
view mRNA expression, structure, and localization changes when prostate cancer cells 
undergo hormone stimulation of the AR growth pathway, changes in androgen 
sensitivity, and other stresses that affect the progression of the disease.   We intended 
to use the information gathered through this technique to assess the importance of AR 
mRNA posttranscriptional regulation in prostate cancer progression. 
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The first aim of this project was to develop molecular beacons that target Androgen 
Receptor mRNA.   This aim was further divided into three sub-aims: A) design AR 
mRNA molecular beacons and determine their functionality, B) optimize the molecular 
beacon approach designed in sub-aim A, and C) validate the molecular beacon 
approach as specific for targeting AR mRNA.   
 
First, beacons were designed based on previously established antisense sites and 
tested in solution for their integrity and in live cells to determine their ability to produce 
visible signal.  Next, the beacons were optimized using two methods: 1) using multiple 
beacons in tandem and 2) changing beacon backbone chemistry.  The optimized system 
was then validated using three different methods.   The first method of validation was to 
demonstrate the ability of the probe(s) to give a reasonable localization pattern.  The 
second method was to show the ability of the probe(s) to distinguish between an AR+ 
and an AR- prostate cancer cell line, LNCaP and DU-145, respectively.  The final 
method of validation was to alter the expression level of AR mRNA in either prostate 
cancer cell line and determine the ability of the probe(s) to follow changes in message 
level.   
 
The second aim of this project was to use the AR mRNA targeted beacon(s) developed 
in the first aim to study the potential role of AR mRNA posttranscriptional regulation in 
two systems important in prostate cancer progression and development: 1) hormone 
induced androgen-dependent prostate cancer cell growth and 2) progression of prostate 
cancer cells from the androgen-dependent to the androgen-independent state.   
 
Our model for studying hormone induced androgen-dependent prostate cancer cell 
growth was to treat the androgen-dependent prostate cancer cell line LNCaP with the 
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synthetic androgen R1881 and evaluate the effects using both comparative quantitative 
real time RT-PCR and AR mRNA visualization with molecular beacons.  To study AR 
mRNA regulation differences between androgen-dependent and androgen-independent 
prostate cancer, we compared AR mRNA expression, structure, and localization in 
androgen-dependent LNCaP cells and androgen-independent LNCaP-derived C4-2 cells 
using our molecular beacon based approach. 
 
If hormone stimulation of androgen-dependent prostate cancer cells produces a visible 
change in AR mRNA regulation, the ability to detect these changes could be enormously 
beneficial.  By using molecular beacons to determine the androgen-induced changes in 
AR mRNA regulation in prostate cancer cells of an unknown state and comparing these 
results to those of known androgen-dependent prostate cancer cells, perhaps you could 
use this information as a diagnostic measure of whether or not the prostate cancer cells 
in question are still in the androgen-dependent phase.  Also, by seeing how androgen-
dependent prostate cancer cells typically respond to hormone stimulation, one could 
determine the ability of a therapeutic to disrupt typical AR mRNA regulation and impede 
this mechanism of cancer growth.  
 
If there are characteristic changes in AR mRNA structure and localization that 
correspond with the transition of prostate cancer cells from androgen-dependent to 
androgen-independent, this method for visualizing AR mRNA could have potential 
diagnostic value in assessing the aggressiveness of the disease. 
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CHAPTER 2: METHODOLOGY 
 
 
 
2.1 Beacon Design 
Molecular beacons were designed to target a unique 16-20 nucleotide long sequence 
within the AR mRNA transcript.  A literature search was performed to find successful AR 
mRNA antisense sites that could function as potential target sequences for our beacons.  
Next, the selected nucleotide sequences were run through the National Center for 
Biotechnology Information’s (NCBI’s) Basic Local Alignment Search Tool (BLAST) to 
ensure that they were specific to AR mRNA.   Once the chosen target sequences were 
verified as potential beacon hybridization domains, stem sequences were selected that 
would allow the beacons to close in the classic hairpin structure in the absence of target 
and have a reasonable melting temperature (in the range of 45-55°C).  Next, Dr. Michael 
Zuker’s Mfold program for nucleic acid folding and hybridization prediction was used to 
determine if our beacon would most probably take on the desired hairpin structure and 
have an appropriate melting temperature. (29)  Ensuring the beacons had an 
appropriate melting temperature is important for avoiding beacon opening at physiologic 
temperatures in the absence of target.   Mfold was run for our desired beacon 
sequences at the physiologic temperature of 37°C and physiologic salt condition of 
150mM NaCl.  Once beacons were designed to meet all the criteria, their sequences 
were sent to be synthesized with a Cyanine dye, Cy3, at the 5’ end, and a quencher, 
Black Hole Quencher 2 (BHQ2), at the 3’ end.  When the beacon folds into the hairpin 
structure, the dye and quencher will be adjacent to each other and fluorescence will be 
quenched.  When the beacon hybridizes to its’ target, the Cy3 dye will displace from the 
quencher and fluorescence will be emitted.  DNA Beacons were ordered from BioSource 
International.  Chimeric beacons were purchased Biosearch Technologies, Inc. and 
Gene LinkTM.   
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2.2 Solution Testing of Molecular Beacons 
All beacons were subjected to solution testing in order to ensure that they take on the 
proper hairpin conformation when not in the presence of their target sequence and open 
and fluoresce when in the presence of their target.  Short synthetic DNA sequences that 
matched the beacon’s target sequence were purchased from IDT, Inc. 
 
Beacons were incubated at a concentration of 200 nM with or without their target 
sequence in 1x nuclease free PBS for 30 minutes at 37 °C. In samples containing the 
target sequence, the target was present at a concentration of 400 nM.  The total 
incubation volume was 50 µL.  The test was performed in triplicate and after incubation 
samples were placed in a black bottom 384-well plate and fluorescence levels were read 
in a Tecan Safire plate reader using 530 nm excitation with a 12 nm bandwidth and 
fluorescence was collected for the range of 560 to 600 nm with a 5 nm step size.   
 
2.3 Cell Culture 
LNCaP, C4-2, and DU-145 cell lines were generously given to us by Dr Leland Chung at 
Emory University.  All three cell lines were grown in the following media formula: RPMI 
1640 with L-Glutamine and Phenol Red (Gibco), 10% Characterized Fetal Bovine Serum 
(HyClone), and 1% 10,000 units/ml penicillin streptomycin (Invitrogen).  Cells were 
passaged in tissue culture treated plastic T-75 filter top flasks using 1x PBS with calcium 
and magnesium (Sigma) and 0.5% trypsin-EDTA (Invitrogen). 
 
For cell starvation, cells were placed into the following media formula, from here on 
referred to as starvation media: RPMI 1640 with L-Glutamine and without Phenol Red 
(Gibco).  For certain treatments, including Vitamin D treatment, cells were placed in the 
following media formula, from here on referred to as depleted media: RPMI 1640 with L-
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Glutamine and Phenol Red, 5% Charcoal/Dextran Treated Fetal Bovine Serum 
(HyClone), and 1% 10,000 units/mL penicillin streptomycin. 
 
Cells treated and used for RNA isolation and subsequent comparative quantitative real 
time RT-PCR were plated at 30-50% confluency in 6-well tissue culture treated plastic 
plates (Corning, Inc. – Costar).  6-well plates were coated with 0.01% Poly-L-Lysine 
solution (Sigma) for 30 minutes at 37°C prior to the addition of cells to promote cell 
adherence. 
 
Cells needed for imaging experiments were plated at 30-50% confluency in 2-chamber 
Lab-Tek II Chamber #1.5 German Coverglass System slides (Nunc). The chamber 
slides were pre-coated with Poly-L-Lysine using the same conditions as listed above. 
 
2.4 RNA Isolation 
 
Cells grown in 6-well plates were collected from the plate using 0.5% trypsin.  The cells 
were pelleted using a microcentrifuge (Eppendorf Centrifuge 5402) at 2000 rpm and 4°C 
for 10 minutes.  The cell pellet was washed with 1x PBS and repelleted at the same 
conditions.  RNA was then isolated from the cell pellets using Ambion®’s PARISTM kit 
without deviation from the product protocol. 
 
2.5 cDNA Synthesis 
cDNA synthesis was performed using Stratagene®’s Affinity ScriptTM Multi Temperature 
cDNA Synthesis kit loading 300ng of RNA per sample.  The product protocol was 
followed explicitly, using Random Primers and the dNTP mix provided with the kit.   
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2.6 Comparative Quantitative Real Time RT-PCR 
Comparative quantitative real time RT-PCR can be used to semi-quantitatively compare 
expression levels between samples by using the control sample’s expression level as a 
reference (100% expression) and reporting experimental sample expression relative to 
this level (percentage of control’s expression).  Samples were prepared using 
Stratagene®’s Brilliant® SYBR® Green QPCR Master Mix and the samples were cycled 
and fluorescence measured using Stratagene®’s MX3005P Real Time PCR Machine.   
 
AR was amplified using the following primers:  
Forward – 5’ CCTGGCTTCCGCAACTTAACAC 3’ and  
Reverse – 5’ GGACTTGTGCATGCGGTACTCA 3’, which produces a 168 base pair (bp) 
product. (30)  β-actin was amplified using the following primers:  
Forward – 5’ ATGGGTCAGAAGGATTCCTATGTG 3’ and  
Reverse – 5’ CTTCATGAGGTAGTCAGTCAGGTC 3’, which produces a 359 bp product. 
(31)  Samples were first denatured at 95 °C for 10 minutes, then run through 40 
amplification cycles of 95 °C for 30 seconds, 58 °C for 60 seconds, and 72 °C for 90 
seconds.  Fluorescence levels were recorded at the end of each 58 °C annealing stage. 
 
Comparative quantitative real time RT-PCR results are always reported in terms of AR 
mRNA expression level normalized by β-actin expression.  Relative expression levels 
are always reported, meaning that the control group (always shown first in graph) is 
calculated to have an expression level of 1, and AR mRNA expression level for all 
treatment groups is reported relative to the control group.  β-actin was explicitly selected 
as the normalizing housekeeping gene due to implications in the literature that GAPDH 
had variable expression levels among different prostate cancer cell lines. (32) 
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2.7 Intracellular Beacon Delivery 
Molecular beacons were delivered using the Streptolysin O (SLO) based reversible 
permeabilization method. (11,13,22,24-26)   2 units/mL SLO was activated for 45 
minutes at 37 °C with 10 mM Tris(2-carboxyethyl)phosphine (TCEP) hydrochloride 
(Sigma) at a final concentration of 10 mM.   50 µL of activated SLO was then added to 
450 µL of media.  Beacons were then added to this mixture at a final concentration of 
750 nM.  The beacon-SLO-media cocktail was then added to a well of the 2-chamber 
slide and the slide was placed in the incubator at 37 °C and 5% CO2 for 10 minutes.  
The cocktail was then removed gently via a micropipettor and fresh media was added to 
the well.  Cells were returned to the incubator for 30 minutes to allow time for beacon 
hybridization and then imaging was performed.  Slides to be kept for later use were fixed 
with 4% nuclease-free paraformaldehyde for 10 minutes at room temperature and stored 
in 1x nuclease-free PBS at 4 °C.   
 
2.8 Total RNA Staining 
SYTO® RNASelectTM green fluorescent cell stain, a nonspecific RNA label from 
Molecular ProbesTM, was used to stain for the total RNA in live cells.   A 500 nM final 
concentration RNASelectTM solution was applied for 30 minutes at 37 °C. Cells were 
then washed in 1x PBS containing calcium and magnesium and placed back into regular 
media before imaging. 
 
2.9 siRNA Transfection 
A literature proven 21-nucleotide AR-targeted siRNA:  
5’ AAGCCCATCGTAGAGGCCCCA 3’ was used to knockdown AR mRNA in LNCaP 
cells.  The control siRNA used by this group was selected as well:  
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5’ ACCCCGGAGATGCTACCCGAA 3’ (Dharmacon®).   (33)   Multiple transfection 
reagents were tested using the conditions listed in the following sections.  RNA was 
isolated or cells were imaged to view AR mRNA knockdown 48 hours post-transfection.  
For all reagents, the starting conditions recommended by the manufacturer were tested.  
For LipofectamineTM 2000, optimization was performed and reported.   
 
2.9.1 LipofectamineTM 2000 
Cells were plated in either 6-well tissue culture treated plates or 2-well chamber slides, 
depending on whether they were used for RNA isolation or imaging experiments, 
respectively.  Cells were plated at least 24 hours before transfection and were 30-50% 
confluent at the time of transfection.   Cells were transfected using a 1 µg siRNA: 4 µl 
LipofectamineTM 2000 ratio.  For a 6-well plate transfection: siRNA was diluted to a final 
volume of 250 µl using serum free RPMI 1640 media.   LipofectamineTM 2000 
(Invitrogen) was also diluted to a final volume of 250 µl using serum free RPMI 1640 
media.  Both the siRNA and LipofectamineTM 2000 solutions were then incubated at 
room temperature for 5 minutes, mixed, and incubated at room temperature for another 
20 minutes.  The solution was then added drop wise to a single well of the plate 
containing 2 mL of fresh media.   This process was proportionally scaled down for use in 
2-well chamber slides based on surface area (5:2).   
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2.9.2 X-tremeGENE 
Cells were transfected at 30-50% confluency.  For a 6-well plate transfection: 2 µg 
siRNA was diluted to a final volume of 100 µl using serum free RPMI 1640 media.  10 µl 
of X-tremeGENE reagent (Roche) was also diluted to a final volume of 100 µl using 
serum free RPMI 1640 media.  Both the siRNA and X-tremeGENE solutions were then 
incubated at room temperature for 5 minutes, mixed, and incubated at room temperature 
for another 15 minutes.  The solution was then added drop wise to a single well of the 
plate containing 1.8 mL of fresh media.    
 
2.9.3 FuGENE® 6 
Cells were transfected at 30-50% confluency.  For a 6-well plate transfection: 3 µl of 
FuGENE® 6 reagent (Roche) was diluted to a final volume of 100 µl using serum free 
RPMI 1640 media and incubated for 5 minutes at room temperature.  2 µg siRNA was 
then added to the solution and incubated for 15 minutes at room temperature. The 
solution was then added drop wise to a single well of the plate containing 1.9 mL of fresh 
media.    
 
2.9.4 OligofectamineTM 
Cells were transfected at 30-50% confluency.  For a 6-well plate transfection: 2.5 µg 
siRNA was diluted to a final volume of 180 µl using serum free RPMI 1640 media.  3 µl 
of OligofectamineTM reagent (Invitrogen) was diluted to a final volume of 15 µl using 
serum free RPMI 1640 media.  Both the siRNA and OligofectamineTM solutions were 
then incubated at room temperature for 5 minutes, mixed, and incubated at room 
temperature for another 20 minutes.  The solution was then added drop wise to a single 
well of the plate containing 1.8 mL of fresh media.    
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2.9.5  DharmaFECT® 3 
Cells were transfected at 30-50% confluency.  For a 6-well plate transfection: 2.5 µg 
siRNA was diluted to a final volume of 200 µl using serum free RPMI 1640 media and 6 
µl of DharmaFECT3® reagent (Dharmacon®) was also diluted to a final volume of 200 µl 
using serum free RPMI 1640 media.  Both the siRNA and DharmaFECT3® solutions 
were then incubated at room temperature for 5 minutes, mixed, and incubated at room 
temperature for another 20 minutes.  The solution was then added drop wise to a single 
well of the plate containing 2.1 mL of fresh media.    
 
2.9.6 CodebreakerTM 
Cells were transfected at 30-50% confluency.  For a 6-well plate transfection: 8 µl of 
CodebreakerTM reagent (Promega) was diluted to a final volume of 625 µl using serum 
free RPMI 1640 media and incubated for 15 minutes at room temperature.  0.4 µg siRNA 
was then added to the solution and incubated for 20 minutes at room temperature. The 
solution was then added drop wise to a single well of the plate containing 2.4 mL of fresh 
media.    
 
2.10 hAR Plasmid Transfection 
hAR, a plasmid containing the full length coding region of human AR, was provided 
courtesy of Dr. Paul Rennie at the University of British Columbia. (34)  The plasmid was 
used to upregulate AR mRNA in DU-145 cells.  Transfection of these cells was 
performed using Roche’s FuGENE® 6 Transfection Reagent.  Cells were ~70-80% 
confluent at the time of transfection.   For a 6-well tissue culture treated plate 
transfection: 3 µl of FuGENE reagent was diluted to a final volume of 100 µl using serum 
free RPMI 1640 media and incubated for 5 minutes at room temperature.  1 µg hAR 
plasmid was then added to the solution and incubated for 15 minutes at room 
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temperature. The solution was then added drop wise to a single well of the plate 
containing 1.9 mL of fresh media.   hAR plasmid effects were examined 2 days post-
transfection.  This process was proportionally scaled down for use in 2-well chamber 
slides based on surface area (5:2).   
 
2.11 Vitamin D Treatment 
Cells were plated in regular media for at least 24 hours before treatment and were not 
treated until 40-50% confluent.  Active Vitamin D, 1α,25-dihydroxyvitamin D3, was used 
at a stock volume of 100 µM in ethanol (EtOH).  For treatment, media was changed to 
depleted media, as described in section 2.3, and Vitamin D was added at a final 
concentration of 100 nM.  An equal volume of EtOH was used to treat control cells.  RNA 
isolation or imaging occurred 24 to 72 hours after treatment.  (35) 
 
2.12 Hormone Starvation Treatment 
Cells were plated in regular media for least 24 hours before starvation treatment.  Cells 
were approximately 30% confluent at the time of treatment.  Cells were then placed in 
starvation media, as described in section 2.3, for a period of 1 to 12 days.  The 
starvation media was changed out every other day to ensure the health of the cells.   
 
2.13 Thapsigargin Treatment 
Cells were plated in regular media for least 24 hours before beginning treatment.  
Thapsigargin was reconstituted at a stock concentration of 100 µM in dimethyl sulfoxide 
(DMSO). When cells were approximately 50-70% confluent, their media was changed to 
starvation media for a period of 16 to 20 hours, and then changed to depleted media 
containing a final concentration of 100 nM thapsigargin.  An equal volume of DMSO was 
used to treat control cells.  RNA isolation or imaging occurred 0 to 24 hours after 
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treatment.  (36)  It is important to note that we kept trials in the 24 hour time frame in 
order to avoid possible apoptotic side effects caused by thapsigargin, which typically 
occur between 2 and 7 days of treatment. (37,38)   
 
Recovery of the cells was also performed by changing out the media on the cells to 
depleted media containing a volume of DMSO equivalent to the volume of thapsigargin 
used in the treatment.  Recovery periods lasted 16 to 48 hours and RNA isolation or 
imaging was performed in this time frame.   
 
2.14 Hormone Stimulation Treatment 
Cells were plated in regular media for least 24 hours before beginning treatment.  1 µM 
synthetic androgen, R1881, in EtOH was a generous gift from our collaborator, Dr. 
Leland Chung, at Emory University. When cells were approximately 40-50% confluent, 
their media was changed to starvation media for a period of 16 to 20 hours, and then 
changed to fresh starvation media containing a final concentration of 10 nM R1881.  An 
equal volume of EtOH was used to treat control cells.   RNA isolation or imaging 
occurred 6 to 48 hours after treatment.  This protocol was also a generous gift from Dr. 
Leland Chung at Emory University. 
 
2.15 Intracellular Imaging 
Early imaging experiments, including initial beacon optimization experiments, were 
conducted using the Zeiss LSM Meta 100 confocal microscope using 100x 
magnification.  Images presented in the rest of this paper were primarily obtained using 
the Zeiss Axiovert 100 with a Zeiss 100x 1.3 numerical aperture (NA) oil lens and a 
Cooke Sensicam SVGA cooled charge-coupled device camera to capture the images. 
For molecular beacon imaging experiments, the Cy3 filter set was used with a 545 nm 
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excitation and 570 nm emission wavelength.  Exposure times of 0.3 to 0.5 seconds were 
used to obtain the fluorescence images.  A uniform exposure time was used for each 
experiment, including beacon signal optimization and AR mRNA regulation experiments.  
Exposure times were reduced gradually from 0.5 to 0.3 seconds for the optimization of 
the AR+ LNCaP vs. AR- DU-145 comparison.  Images were false colored using the 
“black body” color map provided by Adobe Photoshop. 
 
Experiments to quantify molecular beacon fluorescence intracellularly were performed 
on the Applied Precision Deltavision Core system with an Olympus 60x 1.42 NA oil lens 
and an HQ Cool Snap camera.  Again, the Cy3 filter set was used and a uniform 
exposure time of 0.385 seconds was used for this set of experiments.  Cells were 
imaged using 0.2 µm thick slices.  Images were deconvolved and fluorescence was 
quantified using the softWoRx software package associated with the Deltavision Core 
system. 
 
2.16 Quantification of Intracellular Molecular Beacon Signal 
The softWoRx software package associated with the Deltavision Core system was used 
to quantify intracellular molecular beacon signal.  Cells were selected individually and 
their total fluorescence per slice and maximum fluorescence value per slice were 
determined for all cellular slices.   
 
The first characteristic that was determined per cell was average total fluorescence per 1 
µm3 cellular volume.  The total fluorescence per slice for each cell was averaged, 
divided by the surface area of the cell, and divided through again by 0.2 µm to determine 
the average total fluorescence per 1 µm3 cellular volume.   These values were then 
normalized by the average value of this characteristic for the control cells, giving control 
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cells an average value of 1 and the experimental group a relative value.  This 
normalization allowed for the direct merging of several trials for each experiment without 
having to worry about delivery or other variations from trial to trial. 
 
The second characteristic that was determined per cell was average maximum 
fluorescence value.  The average maximum fluorescence value per slice of each cell 
was determined and then these values were normalized in the same manner as 
described above.   
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CHAPTER 3: DEVELOPMENT OF MOLECULAR BEACONS TO TARGET ANDROGEN 
RECEPTOR mRNA 
 
 
 
3.1 Design of Molecular Beacons 
 
3.1.1 Beacon Design 
Using two previously published works that “walked the gene” in order to determine 
accessible antisense sites on AR mRNA, two potential beacon sites were identified.  
(39,40)  The first beacon designed was named AR-24, titled as such because it was 
based on the 24th region tested by one of the publications. (39)  AR-24 is designed to 
hybridize to an 18 nucleotide sequence that is 1784 nucleotides from the start codon of 
the message.  The target sequence was BLASTed to ensure that it was unique to AR 
mRNA and a stem sequence was chosen that gave the beacon an appropriate folding 
conformation at physiologic temperature.  Figure 2 shows the nucleotide sequence of 
AR-24 along with a depiction of the folding conformation of the beacon at physiologic 
conditions of 37 °C and 150 mM NaCl.   
 
AR-24: 5’- /Cy3/ CGAC CAATCATTTCTGCTGGCG GTCG /BHQ-2/ -3’ 
ΔG = -1.87 kcal/mole 
 
TM = 53.7
 o
C 
 
ΔH = -37.2 kcal/mole 
 
ΔS = -113.8 cal/K·mole 
 Figure 2.  AR-24 DNA beacon for targeting AR mRNA.  The molecular beacon 
sequence is listed above.  The underlined bases are part of the molecular beacon stem 
and the bolded bases are part of the hybridization domain.  The thermodynamic 
properties of the beacon as calculated by Mfold are listed and an Mfold produced 
depiction of the beacon structure at physiologic conditions is presented.  (29) 
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The second beacon designed was named AR-7, following the same naming convention. 
AR-7 is designed to hybridize to an 18 nucleotide sequence that starts 1317 nucleotides 
from the start codon.  Again, the same rigorous analysis was preformed to ensure 
uniqueness of the targeted sequence and an appropriate stem was chosen to allow for 
proper hairpin conformation of the beacon.  In figure 3, the nucleotide sequence of AR-7 
is listed along with the folding conformation of the beacon.   
 
AR-7: 5’- /Cy3/ CCGTG ATACAACTGGCCTTCTTC CACGG /BHQ-2/ -3’ 
ΔG = -1.72 kcal/mole 
 
TM = 50.9
 o
C 
 
ΔH = -39.5 kcal/mole 
 
ΔS = -121.9 cal/K·mole 
 
Figure 3.  AR-7 DNA beacon for targeting AR mRNA.  The molecular beacon 
sequence is listed above.  The underlined bases are part of the molecular beacon stem 
and the bolded bases are part of the hybridization domain.  The thermodynamic 
properties of the beacon as calculated by Mfold are listed and an Mfold produced 
depiction of the beacon structure at physiologic conditions is presented.  (29) 
 
 
3.1.2 Solution Testing of Beacons 
Both beacons functioned as expected.  Their fluorescence was quenched when the 
beacon was not in the presence of target, with minimal noise detected at the Cy3 
emission wavelength.  Table 1 shows the signal-to-background ratio for each beacon at 
Cy3’s optimal emission wavelength, 570nm. 
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Table 1.  Signal-to-background ratio for AR molecular beacons at 570 nm.  The 
signal-to-background ratio was calculated by measuring the fluorescence emission at 
570 nm for beacons exposed to target and then dividing by the fluorescence emission at 
570 nm for beacons in the absence of target.  The ratio was calculated in three 
independent trials and the average and standard deviation are reported for both AR-7 
and AR-24. 
 Signal-to-Background Ratio 
at 570 nm emission 
AR-7 17.408 ± 0.812 
AR-24 43.526 ± 3.081 
 
 
3.1.3 Testing Molecular Beacons Intracellularly 
Molecular beacons were introduced to cells using the Streptolysin O method discussed 
in section 2.7.  Both beacons were tested individually in the AR+ prostate cancer cell 
line, LNCaP.  In figure 4, the results of the preliminary test are shown indicating that the 
beacons do produce signal intracellularly.  Whether this signal is specific will be explored 
in section 3.3.  The next section will discuss the optimization the beacons to allow for 
maximal signal-to-background intracellularly. 
 
 
Figure 4.  AR-7 and AR-24 molecular beacon signal in LNCaP cells.  This figure 
shows LNCaP cells cultured in two-well glass chamber slides that have had A) AR-7 or 
B) AR-24 introduced via SLO permeabilization.  White light and Cy3 fluorescence 
signals have been coregistered to show signal localization. 
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3.2   Optimization of Molecular Beacons 
In section 3.1, the design of two potential AR mRNA targeted beacons, AR-7 and AR-24, 
were discussed.  The solution study confirmed that these beacons folded properly, with 
minimum noise in the Cy3 channel and strong signal-to-background ratios when in the 
presence of their synthetic targets.  In anticipation that the signal-to-background will 
greatly diminish when imaging the beacon signal intracellularly, two methods were 
explored for amplifying the signal-to-background ratio and these methods will be 
discussed in the following sections: 1) using multiple beacons in tandem and 2) 
modifications of the beacon backbone chemistry. 
 
3.2.1 Using Multiple Beacons to Amplify Targeted Molecular Beacon Signal 
The first method explored for amplifying the signal-to-background ratio when imaging AR 
mRNA intracellularly was the possibility of using both molecular beacons designed in 
tandem.  Using the AR+ model prostate cancer cell line LNCaP, the two designed 
beacons, AR-7 and AR-24, were tested individually and in tandem to determine if the 
targeted signal could be boosted when multiple probes are hybridized to the same 
mRNA target.  In figure 6 in section 3.2.2, images depicting the intracellular signal 
emitted from AR-7 individually, AR-24 individually, and the two beacons used in tandem 
are provided alongside with the results for enhancing signal-to-background using altered 
molecular beacon chemistry.  The use of the beacons in tandem does appear to aid in 
amplifying the targeted signal, improving the signal-to-background ratio in the image. 
 
3.2.2 Changing Beacon Backbone Chemistry 
The second approach that was used to enhance the signal-to-background ratio for 
intracellular imaging of the beacons was to change the backbone chemistry of the 
molecular beacons.  The beacons discussed in section 3.1 were designed with a 
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standard DNA backbone.  Since we are targeting mRNA, the hybridization of these 
beacons with target mRNA requires a DNA-RNA interaction.  An RNA-RNA interaction 
would be more energetically favorable for beacon-target binding and perhaps lead to a 
greater amount of beacons binding to the target mRNA, thereby enhancing the signal-to-
background ratio in the intracellular imaging of these probes.  Due to this theory, two 
new molecular beacons were designed based on the hybridization domains of AR-7 and 
AR-24.  The new beacons, AR-7R and AR-24R, are chimeric beacons with 2’-O-Me 
RNA bases in the hybridization loop of the beacons, and a maintained DNA stem holding 
the beacon closed when in the absence of target.  These new beacons will provide the 
more energetically favorable RNA-RNA interaction for beacon-target binding by having 
2’-O-Me RNA bases in the hybridization domain.  The sequences for AR-7R and AR-
24R are listed below in figure 5.  These beacons were also solution tested to ensure that 
they still properly conformed and remained closed in absence of target. 
 
AR-7R: 5’- /Cy3/ CCGTGT AUACAACUGGCCUUCUUC ACACGG /BHQ-2/ -3’                             
AR-24R: 5’- /Cy3/ CCTAC CAAUCAUUUCUGCUGGCG GTAGG /BHQ-2/ -3’ 
Figure 5.  AR-7R and AR-24R: chimeric versions of AR-7 and AR-24 molecular 
beacons.  The molecular beacon sequences are listed above.  The underlined bases 
are part of the molecular beacon stem and the bolded bases are part of the hybridization 
domain.  Note that the bases in the hybridization domain are now 2’-O-Me RNA. 
 
 
Direct comparisons between AR-7 and AR-7R, AR-24 and AR-24R, and AR-7 + AR-24 
and AR-7R + AR-24R were performed in LNCaP cells to demonstrate the improvement 
in signal-to-background that was achieved by modifying the backbone chemistry of the 
probes.  The results are depicted in figure 6.  This figure also allows you to compare 
signal from AR-7R to AR-24R and to AR-7R + AR-24R to further demonstrate the utility 
of using multiple beacons in tandem as discussion in section 3.2.1.   As is evidenced 
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from the representative images, use of both the beacons in tandem with the improved 
chimeric backbone chemistry provided for the best signal-to-background in the 
intracellular imaging of AR mRNA.   
 
 
Figure 6.  Optimization of AR mRNA imaging through the use of multiple beacons 
in tandem and altering beacon backbone chemistry.  AR-7, AR-24, AR-7R, and AR-
24R were introduced individually or in tandem to LNCaP cells in order to determine the 
value of using multiple beacons and the value of using the chimeric chemistry to boost 
beacon signal.  All beacons were introduced at the same concentration and imaged at 
the same exposure conditions.  Panel A shows the coregistration of the Cy3 
fluorescence with the white light image to show cellular localization of signal. Panel B 
shows the Cy3 fluorescence alone to enable better comparison of the signal levels.  By 
comparing AR-7 + AR-24 to both AR-7 alone and AR-24 alone or by comparing AR-7R + 
AR-24R to both AR-7R alone and AR-24R alone, the utility of using multiple beacons in 
tandem is evident.  By comparing AR-7 to AR-7R, AR-24 to AR-24R, and AR-7 + AR-24 
to AR-7R + AR-24R, the utility of changing to the chimeric chemistry is clear.   
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3.3 Validation of Molecular Beacons 
 
3.3.1 Feasibility of AR mRNA Granular Pattern 
There were several approaches used to prove that this optimized dual chimeric beacon 
system for tracking AR mRNA was in fact specifically binding to the desired target.  The 
first approach was to determine the feasibility of the granular AR mRNA organization 
pattern being visualized through the use of the probe system.  This determination of 
feasibility was achieved two ways: 1) total RNA staining to determine the typical 
localization patterns of RNA in the LNCaP model cell line and 2) an examination of the 
literature to determine if similar localization patterns for RNA have been see before and 
if proteins known to bind to this mRNA localize in this granular fashion. 
 
LNCaP cells were stained with RNA select and their traditional RNA localization patterns 
are shown in figure 7.  The localization pattern is granular in nature, which matches 
perfectly with the granular pattern that we see for AR mRNA using our probe system.  Of 
course the total RNA stain shows many more granules than our probe system, which is 
also supportive of our system, because if our system is specifically labeling our desired 
target, then only a small subpopulation of the total cellular RNA should be labeled.   
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Figure 7.  RNA localization in LNCaP cells.  A nonspecific RNA Stain, RNASelectTM, 
was used to visualize the general localization of mRNA in LNCaP cells.  A) Shows a 
white light and green fluorescence coregistration to demonstrate cellular localization of 
the RNA. B) Shows the fluorescence image alone to more clearly articulate the granular 
structure of the RNA. 
 
 
 
A granular RNA pattern has been seen before in the literature.  Specifically, Dr. Robert 
Singer’s group has demonstrated via Fluorescent In-Situ Hybridization (FISH) that β-
actin mRNA has a granular pattern in fibroblasts and neurons. (41,42)  Also, Dr. Jack 
Keene’s group has shown Elav-Hu RNA-binding proteins known to colocalize with a 
family of mRNAs, including AR mRNA, organizing in a granular pattern in neurons.  (43)  
But perhaps the most convincing piece of supporting evidence is that visualization of AR 
mRNA in the rat prostate gland using FISH also showed AR mRNA structure to be 
granular in nature. (44)   
 
3.3.2 AR+ vs. AR- Prostate Cancer Cell Line Comparison 
The next step for validating this probe system was to compare the beacon signal levels 
in an AR+ and an AR- prostate cancer cell line.  Intracellular signal from the AR+ 
prostate cancer cell line LNCaP, which served as our model cell line for testing and 
optimizing our probes, was compared to the signal emitted from the AR- prostate cancer 
cell line DU-145.  Figure 8 shows the intracellular signal levels in both cell lines using our 
optimized AR-7R + AR-24R probe system.   
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Figure 8.  Validation of dual chimeric beacon approach for visualizing AR mRNA 
using AR+ LNCaP vs. AR- DU-145 cell line comparison.  AR-7R and AR-24R were 
used in tandem and delivered to A) AR+ LNCaP cells and B) AR- DU-145 cells.  The 
relatively low signal levels in the DU-145 cells compared to the LNCaP cells is an 
important observation in proving probe specificity. 
 
 
 
In figure 9, you can see the progression of this AR+ vs. AR- cell line comparison as the 
probe system was optimized from a single DNA probe to two chimeric probes.  The 
enhancement of signal to noise afforded by the optimized system allowed for reduction 
in image exposure time, permitting the AR+ vs. AR- cell line comparison to become 
increasingly more disparate.   
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Figure 9.  Demonstration of how dual chimeric beacon system affords more 
disparate comparison between LNCaP and DU-145 cell lines.  AR-7, AR-24, AR-7R, 
and AR-24R were introduced individually or in tandem to A) LNCaP cells or B) DU-145 
cells.  Due to increased beacon signal intensity through the use of multiple beacons and 
chimeric backbone chemistry, it was possible to lower the image exposure time to allow 
the DU-145 cells to appear more “negative” while still showing strong positive signal 
from the LNCaP cells.  Using the optimized dual chimeric system allowed for the most 
disparate comparison between the AR+ and AR- prostate cancer cells lines. 
 
 
 
Total RNA staining was used to demonstrate that the typical organization of RNA in DU-
145 cells does not agree with the faint signals seen from the AR molecular beacons.  As 
seen in figures 8 and 9, the localization of the faint signals seen in DU-145 cells from AR 
molecular beacons is spotty and perinuclear.  The total RNA staining of DU-145 cells in 
figure 10 shows that the general localization of RNA for this cell type is mitochondrial in 
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nature.   This leads us to believe that the beacon signal seen in DU-145 cells is non-
specific noise in the cell and not from beacons hybridizing to RNA. 
 
 
Figure 10.  RNA localization in DU-145 cells.  A nonspecific RNA Stain, RNASelectTM, 
was used to visualize the general localization of mRNA in DU-145 cells.  A) Shows a 
white light and green fluorescence coregistration to demonstrate cellular localization of 
the RNA. B) Shows the fluorescence image alone to more clearly articulate the 
mitochondrial localization of the RNA. 
 
 
 
3.3.3 siRNA Knockdown of AR mRNA in AR+ Prostate Cancer Cell Line 
 
The next approach attempted to validate AR mRNA targeted molecular beacons was to 
take our model AR+ prostate cancer cell line, LNCaP, and induce significant knockdown 
AR mRNA levels using siRNA.  An AR siRNA sequence was selected from the literature 
(33), and multiple transfection reagents were tested for their ability to induce AR mRNA 
knockdown.  LipofectamineTM 2000 was the first transfection reagent tested.  Figure 11 
shows the knockdown achieved by LipofectamineTM 2000 48 hours post transfection for 
3 different concentrations of siRNA.  The third transfection condition of 1.2 µg siRNA/mL 
total volume was used due to its’ repeatable high knockdown efficiency of ~85%.  It is 
important to consider that the knockdown level needs to be relatively high in order to 
ensure the ability to visualize AR mRNA level changes due to the inherently low levels of 
signal-to-background when imaging mRNA intracellularly.   
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Figure 11.  AR mRNA knockdown in LNCaP cells using siRNA introduced via 
LipofectamineTM 2000.  An AR mRNA specific siRNA was used to knockdown AR 
mRNA in LNCaP cells.  Three different siRNA concentrations were tested, 0.5 µg/mL 
total volume, 0.86 µg/mL total volume, and 1.2 µg/mL total volume, with the highest 
concentration giving the best knockdown levels, 84.07 ± 0.77%.  A control siRNA was 
used at the highest concentration in order to show that the knockdown effect was not 
nonspecific. 
 
 
Once LipofectamineTM 2000 transfection conditions had been optimized, the siRNA 
knockdown was performed on LNCaP cells and AR mRNA was detected using the dual 
chimeric beacon approach.  Figure 12 demonstrates the effects of the AR mRNA 
knockdown using LipofectamineTM 2000 on AR mRNA targeted beacon signal.   
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Figure 12.  Visualization of AR mRNA after siRNA induced knockdown via 
LipofectamineTM 2000.  AR mRNA was visualized using the dual chimeric beacon 
system.  Signal levels in A) Non-treated LNCaP cells were compared with B) AR siRNA 
treated cells, 1.2 µg siRNA/mL total volume.  In panel B, an overall drop in signal level 
could be argued, but the development of vesicles within the cell that often contain bright 
beacon signal was troubling.   
 
 
As is evident from the images in figure 12, overall you might say that there is a 
diminishment of beacon signal in the siRNA treated LNCaP cells, however, there are 
large vesicles that have developed within the cell, presumably due to the transfection 
reagent.  LipofectamineTM 2000’s responsibility for the vesicle development will be 
shown later in this section when cells were exposed to a variety of transfection reagents 
without the presence of siRNA in order to determine the effect of the transfection 
reagents on LNCaP morphology.  It appears that these large vesicles often colocalize 
with bright signal from the beacons (figure 13).   
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Figure 13.  Localization of AR beacon signal in LipofectamineTM 2000 delivered AR 
siRNA treated LNCaP cells.  AR mRNA was visualized using the dual chimeric beacon 
system.  AR mRNA levels were knocked down in LNCaP cells via LipofectamineTM 2000 
delivered AR siRNA, 1.2 µg/mL total volume.  A) Shows a white light image of a treated 
LNCaP cell with the treatment induced vesicles circled in green.  The vesicle that 
contained strong beacon signal is surrounded with a dashed green line.  B) Shows the 
coregistration of the Cy3 fluorescence image with the white light image, indicating the 
presence of high fluorescence signal in the vesicle surrounded by the dashed green line.  
As is evident by the other circled vesicles, not all vesicles contain strong beacon signal.  
Some contain moderate to no beacon signal.  
 
 
 
It is our hypothesis that these vesicles are trapping and degrading the beacons, but this 
would be extremely difficult to prove.  However, the shear fact that this transfection 
reagent has such a profound effect on the cell morphology makes it difficult to believe 
that the signal level changes seen in the treated cells are truly indicative of AR mRNA 
level changes.  It could be postulated that using cells treated only with LipofectamineTM 
2000 would be a better control, but since the vesicle development occurs in that case as 
well, it would be difficult to ascertain whether or not there are true AR mRNA signal level 
changes when the cells have developed vesicles that appear to contain a large fraction 
of the beacons that have been introduced to the cells.   
 
We felt it was important to use a system that does not have such a drastic effect on cell 
morphology for validating our probe system.  We moved on to test the effects of several 
transfection reagents including FuGENE® 6, X-tremeGENE, OligofectamineTM, 
CodebreakerTM, and DharmaFECT® 3 on both AR mRNA knockdown and cell 
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morphology.  It was found that the mildest reagent on the cells in terms of changes to 
cell morphology was FuGENE® 6, but this reagent also had no effect on AR mRNA 
knockdown, making it a poor choice.  CodebreakerTM also had limited effects on cell 
morphology and AR mRNA knockdown.  X-tremeGENE caused considerable cell death 
with minimal effect on AR mRNA level and DharmaFECT® 3 also caused considerable 
cell death with moderate effect on AR mRNA level (~50% knockdown).  
OligofectamineTM caused minimal changes to cell morphology and about 50% 
knockdown of AR mRNA.  The effects of the different transfection reagents on AR 
mRNA knockdown and LNCaP cell morphology are shown in figures 14 and 15, 
respectively. 
 
 
Figure 14.  siRNA induced AR mRNA knockdown using different transfection 
reagents.  Several transfection reagents were tested for their ability to knockdown AR 
mRNA, including: LipofectamineTM 2000, FuGENE® 6, X-tremeGENE, OligofectamineTM, 
CodebreakerTM, and DharmaFECT® 3.  All reagents were tested at their initial 
manufacturer recommended conditions: LipofectamineTM 2000 (0.86 µg siRNA/mL total 
volume), FuGENE® 6 (1 µg siRNA/mL total volume), X-tremeGENE (1 µg siRNA/mL total 
volume), OligofectamineTM (1.25 µg siRNA/mL total volume), CodebreakerTM (0.133 µg 
siRNA/mL total volume), and DharmaFECT® 3 (1 µg siRNA/mL total volume).  FuGENE® 
6, X-tremeGENE, and CodebreakerTM provided for minimal to no AR mRNA knockdown.  
LipofectamineTM 2000, OligofectamineTM, and DharmaFECT® 3 provided for at least 50% 
knockdown. 
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Figure 15.  LNCaP cell morphology changes due to siRNA transfection reagents. 
Several transfection reagents were tested to determine their effects on LNCaP cell 
morphology.  No siRNA was used in this experiment.  The concentration of transfection 
reagent used is described in section 2.9 and is identical to that used in the experiment 
shown in Figure 14.   LNCaP cells were visualized after treatment with the following 
transfection reagents: A) LipofectamineTM 2000, B) FuGENE® 6, C) X-tremeGENE, D) 
OligofectamineTM, E) CodebreakerTM, and F) DharmaFECT® 3.  Green circles indicate 
the development of intracellular vesicles, while red circles indicate the presence of dead 
cells and cell debris.  FuGENE® 6 caused the least change in cell morphology, followed 
by CodebreakerTM and OligofectamineTM.  However, of those three, only 
OligofectamineTM induced any AR mRNA knockdown.  
 
 
 
OligofectamineTM’s ability to moderately knockdown AR mRNA with limited changes in 
cell morphology encouraged us to attempt to optimize this reagent in order to get higher 
levels of knockdown, while maintaining cell morphology, however, we were unsuccessful 
(data not shown).  At this point, using siRNA as a method for validating our probe 
system was abandoned and other methods were pursued. 
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3.3.4  Upregulation of AR mRNA in an AR- Prostate Cancer Cell Line through the 
use of a Plasmid System 
 
Due to the lack of success in modulating AR mRNA levels in the LNCaP cell line via 
siRNA, a second approach to modulate AR mRNA expression within the same cell line 
was explored.  We attempted to upregulate AR in our AR- prostate cancer cell line 
model, DU-145, using a human Androgen Receptor (hAR) plasmid that was provided by 
Dr. Paul Rennie’s lab at the University of British Columbia. (34)  Fortunately, FuGENE® 
6, which was shown to be the gentlest transfection reagent on cell morphology in the 
section 3.3.3, successfully delivered the hAR plasmid to DU-145 cells as shown via 
comparative quantitative real time RT-PCR in figure 16.  
  
 
Figure 16.  Upregulation of AR mRNA in DU-145 cells using an hAR plasmid.  hAR 
plasmid was introduced to DU-145 cells by FuGENE® 6 to upregulate AR mRNA levels 
in this AR- prostate cancer cell line.  AR mRNA levels rose to 122.07 ± 37.66 fold higher 
than that of the AR+ prostate cancer cell line, LNCaP.  DU-145 AR mRNA levels are 
naturally over 230 times less than that of LNCaP cells, making it an AR- prostate cancer 
cell line. 
 
 
Now that a method for upregulating AR mRNA levels in DU-145 cells had been 
established, the next step was to image the increase in AR mRNA expression using our 
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molecular beacon system.  As you can see from figure 17, it was impossible to detect an 
increase in AR mRNA beacon signal in DU-145 cells transfected with hAR plasmid.   
 
 
Figure 17.  Visualization of AR mRNA in DU-145 cells transfected with hAR 
plasmid.  AR mRNA was visualized using the non-optimized AR-7 + AR-24 DNA 
beacon system.  Even with the non-optimized system, it is evident that you cannot see a 
difference between A) DU-145 cells and B) DU-145 cells + hAR plasmid, despite the 
dramatic increase in AR mRNA level afforded by the plasmid. 
 
 
In order to determine if there was indeed some form of RNA being produced from the 
plasmid, the general RNASelectTM stain was used to stain DU-145 cells that had been 
transfected with the plasmid.  As you can see from figure 18, the localization of the 
mRNA in the hAR plasmid transfected cells contains large masses of RNA that do not 
localize similarly to the endogenous RNA of the cell.  Traditionally, DU-145 cells have a 
mitochondrial localization to their RNA and these large masses do not fit in with this 
pattern.   
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Figure 18.  RNA localization in DU-145 cells transfected with hAR plasmid.  A 
nonspecific RNA Stain, RNASelectTM, was used to visualize the localization of all RNA in 
1) DU-145 cells and 2) DU-145 Cells transfected with hAR plasmid.  A) Shows a white 
light and green fluorescence coregistration to demonstrate cellular localization of the 
RNA. B) Shows the green fluorescence image alone to more clearly articulate the 
accumulation of large RNA globules in hAR plasmid-transfected DU-145 cells. 
 
 
It was then speculated that since the plasmid did not contain the untranslated regions of 
AR mRNA, the mRNA localization proteins that typically bind to AR mRNA were not 
present, causing the AR mRNA produced to form an amorphous mass.  It was also 
probable that the AR mRNA produced from the plasmid did not take on the same 
conformation as the endogenous AR mRNA due to the lack of the untranslated regions.  
With an altered conformation, the accessible sites on AR mRNA will most likely be 
different from what they are when the mRNA is in its’ endogenous form, making sites 
that were originally accessible to our beacons now inaccessible.  The clustering of the 
mRNA into a large mass and changes in site accessibility on the mRNA might make it 
impossible for our beacons to hybridize to AR mRNA, making visualization improbable 
with our probe system.  Therefore, the inability of our beacons to detect the upregulation 
of  AR mRNA in DU-145 cells when they are transfected with hAR plasmid most likely is 
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not due to the beacons not accurately targeting AR mRNA, but rather due to the fact that 
the mRNA produced from the plasmid did not behave similarly to the endogenously 
produced mRNA.   
 
3.3.5 Regulation of AR mRNA in an AR+ Prostate Cancer Cell Line via Indirect 
Signaling Methods 
 
3.3.5.1 Upregulating AR mRNA by Vitamin D 
It has been shown in the literature that Vitamin D can upregulate AR mRNA in LNCaP 
cells. (35,45)  We attempted to harness this AR mRNA regulation method for validating 
our probe system.  In figure 19, a time course for Vitamin D treatment was conducted in 
order to determine the optimal time point for maximal upregulation of AR mRNA.  
According to the literature, this time point should be 48 hours, and our results agreed 
with that time frame.  The literature, however, showed a much higher maximal 
expression level, an 8 to 10-fold increase, than what we saw from this experiment, about 
a 2-fold increase.  (35) 
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Figure 19.  Upregulation of AR mRNA in LNCaP cells using Vitamin D.  LNCaP cells 
were exposed to 100 nM Vitamin D treatment for a period 0, 24, 48, or 72 hours.  AR 
mRNA relative expression level shows a 2-fold increase in AR mRNA expression level at 
48 hours. 
 
 
Considering the diminishment of the signal-to-background ratio when imaging the 
beacons intracellularly, there was concern that this minimal of an expression level 
change would be difficult to detect.  In figure 20, AR mRNA was imaged in untreated and 
100 nM Vitamin D treated cells using our dual chimeric beacon approach.  It could be 
argued that there is slightly more intense signal in the Vitamin D treated cells, but the 
change is not drastic enough to be a convincing piece of proof towards probe specificity.   
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Figure 20.  Visualization of AR mRNA in LNCaP cells treated with 100 nM Vitamin 
D for 48 hours. AR mRNA was visualized using the dual chimeric beacon system.  
LNCaP cells were either 1) not treated or 2) treated with 100 nM Vitamin D for 48 hours.  
A) Shows a white light and Cy3 fluorescence coregistration to demonstrate cellular 
localization of AR mRNA. B) Shows the fluorescence image alone to make the 
fluorescence level differences clearer.  The difference between beacon signal level in 
non-treated versus Vitamin D treated LNCaP cells is not definitely discernible. 
 
 
3.3.5.2  Upregulating AR mRNA by Hormone Starvation 
A suggestion given to us by our collaborator at Emory University, Leland Chung, Ph.D. 
and by the literature, was to starve LNCaP cells from hormones for several days to 
induce the cells to upregulate their AR mRNA levels and stability in order to continue 
making AR protein. (16)   A time course was conducted to determine the increase in AR 
mRNA expression level over a course of 12 days of hormone starvation.  The results of 
this time course are displayed in figure 21. 
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Figure 21.  Upregulation of AR mRNA in LNCaP cells via hormone starvation.  
LNCaP cells were incubated with starvation media, as described is section 2.12, for a 
period of up to 12 days.  AR mRNA relative expression level was determined at 0, 3, 5, 
6, 7, 9, and 12 days.  AR mRNA levels reached their peak at 6 days, but the increased 
expression was less than 2-fold above the 0 day control. 
 
 
As is evident from the results of the time course, AR mRNA levels rise until they peak at 
6 days and then continue to drop off.  At no point during the time course do levels rise 
above a 2-fold increase.  Due to the difficulty in imaging the 2-fold increase induced by 
Vitamin D treatment, as discussed in section 3.3.5.1, this method was abandoned as a 
possible route for probe validation.   
 
3.3.5.3  Downregulating AR mRNA by Thapsigargin 
Gong et al. showed in 1995 that thapsigargin, a calcium ionophore, could be used 
regulate AR mRNA levels with precise temporal control. (36)  Their work showed that 
after 100 nM thapsigargin was applied to LNCaP cells, the levels of AR mRNA 
decreased sharply until about 6 hours, and at 16 hours the levels began to recover. (36)  
We repeated this time course (figure 22) and determined that we could reach a maximal 
level of knockdown of ~80-85% between 6 and 16 hours post-treatment. 
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Figure 22.  Downregulation of AR mRNA in LNCaP cells using thapsigargin.  
LNCaP cells were exposed to 100 nM Thapsigargin treatment for up to 24 hours.  AR 
mRNA relative expression levels were determined at 0, 2, 3, 4, 6, 16, 20, and 24 hours 
post-treatment.  Maximal knockdown in AR mRNA expression was found to occur 
between 6 and 16 hours of treatment, at a level between 80 and 85% knockdown.  
 
 
The next step was to determine if we could visualize this drastic decrease in AR mRNA 
level using our molecular beacons.  The visual change might not be as striking as that 
indicated with comparative quantitative real time RT-PCR, but the 5:1 to 10:1 control to 
treated comparison should be detectable even with the reduced signal-to-background 
afforded by epifluorescent imaging.  As is seen in figure 23, the decrease in AR mRNA is 
detectable with our dual chimeric beacon system.   
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Figure 23.  Visualization of thapsigargin induced AR mRNA knockdown in LNCaP 
cells.  AR mRNA was visualized using the dual chimeric beacon system.  LNCaP cells 
were either 1) not treated or 2) treated with 100 nM thapsigargin for 6 hours.  A) Shows 
a white light and Cy3 fluorescence coregistration to demonstrate cellular localization of 
AR mRNA. B) Shows the fluorescence image alone to make the fluorescence level 
differences clearer.  The difference between beacon signal level in non-treated vs. 
thapsigargin treated LNCaP cells is clearly visible. 
 
 
 
The next step was to see if our beacons could detect the recovery of AR mRNA after 
thapsigargin treatment.  LNCaP cells were treated with 100 nM thapsigargin for 6 hours 
and then their media was replaced and the cells were allowed to recover for 16-48 
hours.  The level of AR mRNA after 24 hours of recovery was to approximately 60% of 
the original level (figure 24).   
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Figure 24.  Recovery of AR mRNA expression in LNCaP cells after thapsigargin 
treatment is removed.  LNCaP cells were exposed to 100 nM thapsigargin treatment 
for 6 hours and then their media was changed out to fresh media not containing 
thapsigargin.  LNCaP cells were allowed to recover for a period of up to 48 hours and 
AR mRNA relative expression levels were determined after 16, 24, and 48 hours of 
recovery.  At 24 hours of recovery time, AR mRNA levels had returned to 58.63 ± 3.11% 
of that of non-treated control cells. 
 
 
This information indicates that the comparison of thapsigargin 6 hour treatment + 24 
hour recovery to thapsigargin 6 hour treatment is about 3:1 to 6:1, which has a good 
probability of being visually detectable.  However, the comparison of no treatment 
control to thapsigargin 6 hour treatment + 24 hour recovery is less drastic and might not 
be detectable.  In figure 25, the intracellular visualization of these three points in this 
time course is presented.  It is clear that you can see the recovery of AR mRNA signal in 
LNCaP cells after 24 hours of recovery time post-thapsigargin treatment.  The visual 
confirmation that our probes can follow these temporal changes in AR mRNA adds to 
our argument that these beacons specifically target AR mRNA.   
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Figure 25.  Visualization of thapsigargin induced AR mRNA knockdown and post-
treatment AR mRNA recovery in LNCaP cells.  AR mRNA was visualized using the 
dual chimeric beacon system.  LNCaP cells were either: 1) not treated, 2) treated with 
100 nM thapsigargin for 6 hours, or 3) treated with 100 nM thapsigargin for 6 hours and 
then allowed to recover for 24 hours.  A) Shows a white light and Cy3 fluorescence 
coregistration to demonstrate cellular localization of AR mRNA. B) Shows the 
fluorescence image alone to make the fluorescence level differences clearer.  The 
recovery of AR mRNA signal 24 hours after stopping thapsigargin treatment (Panel 3) is 
evident. 
 
 
While the imaging was convincing in and of itself, we attempted to quantify the 
fluorescence levels within LNCaP cells at each phase of this thapsigargin time course.  It 
was clear due to the limitations of signal-to-background with imaging that the changes 
we would see between the two groups would not be as drastic as those seen with our 
comparative quantitative real time RT-PCR results.  It was unclear whether or not the 
difference between non-treated and recovered cells would be quantifiably detectable due 
to the minimal difference between these levels (less than 2:1).  The difference between 
control and thapsigargin treated cells and the difference between thapsigargin treated 
cells and recovered cells would hopefully be able to be confirmed via fluorescence 
quantification due to their more drastic differences in expression level.  
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In figures 26 and 27, the quantification results are reported for both average total cellular 
fluorescence per unit of cellular volume and for average maximum fluorescence intensity 
per cell, respectively.  As you can see, the thapsigargin treated cells have lower average 
total cellular fluorescence and lower maximum fluorescence than either the control or the 
recovered groups, but the difference between the control and the recovered group is 
indistinguishable on both counts.  This is perhaps due to the limited difference in AR 
mRNA level between the two groups, less than 2:1.  Overall, the changes seen through 
quantification are not nearly as drastic as those seen visually and through PCR.  
Possible reasons for the poor quantification results will be explored in Chapter 5. 
 
 
Figure 26.  Quantification of average AR beacon fluorescence per 1 µm3 cellular 
volume in non-treated, thapsigargin treated, and post-thapsigargin treatment 
recovered LNCaP cells.  Non-treated, 100 nM thapsigargin 6 hour treated, and 100 nM 
thapsigargin 6 hour treated + 24 hour recovered cells were all incubated with the dual 
chimeric beacon system to allow for AR mRNA visualization.  Using the softWoRx 
software package, average fluorescence per 1µm3 cellular volume was calculated for a 
series of cells in each treatment group.  Their values were averaged and normalized by 
the average value of the control non-treated group.  Relative fluorescence levels for 
these three treatment groups are reported above.  The 100 nM thapsigargin 6 hour 
treatment group did have lower fluorescence levels, and a recovery of fluorescence for 
the 100 nM thapsigargin 6 hour + 24 hour recovery treatment group was observed.  
However, the changes in fluorescence are not significant and are not nearly as dramatic 
as the comparative quantitative real time RT-PCR and the visualization results. 
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Figure 27.  Quantification of average maximum AR beacon fluorescence per cell in 
non-treated, thapsigargin treated, and post-thapsigargin treatment recovered 
LNCaP cells.  Non-treated, 100 nM thapsigargin 6 hour treated, and 100 nM 
thapsigargin 6 hour treated + 24 hour recovered cells were all incubated with the dual 
chimeric beacon system to allow for AR mRNA visualization.  Using the softWoRx 
software package, average maximum fluorescence per cell was calculated for a series of 
cells in each treatment group.  Their values were averaged and normalized by the 
average value of the control non-treated group.  Relative fluorescence levels for these 
three treatment groups are reported above.  Again, the 100 nM thapsigargin 6 hour 
treatment group did have lower fluorescence levels, and a recovery of fluorescence for 
the 100 nM thapsigargin 6 hour + 24 hour recovery treatment group was observed.  But 
just as before, the changes in fluorescence are not significant and are not nearly as 
dramatic as the comparative quantitative real time RT-PCR and the visualization results. 
 
 
Overall, the thapsigargin time course proved a useful tool for proving the specificity of 
our dual chimeric beacon approach for targeting and tracking AR mRNA, but the method 
of fluorescence quantification needs to be investigated to hopefully provide more 
convincing results. 
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CHAPTER 4: UTILIZING ANDROGEN RECEPTOR mRNA TARGETED MOLECULAR 
BEACONS TO STUDY POSTTRANSCRIPTIONAL MECHANISMS INVOLVED IN 
PROSTATE CANCER PROGRESSION 
 
 
 
4.1 Studying AR mRNA Posttranscriptional Regulation Changes in AR+ Androgen-
Dependent Prostate Cancer Cells Responding to Hormone Stimulation 
 
In its’ earlier stages, prostate cancer responds to hormone stimulation by the androgens 
testosterone and DHT.  The ability of androgens to promote prostate cancer cells to 
continue growing and dividing is the principal reasoning behind using androgen ablation 
therapy as a treatment for prostate cancer.  The hope is that by removing the stimulus, 
any prostate cancer cells left after surgery will no longer be promoted to grow.   
 
As was stated in the section 1.1, testosterone works to promote prostate cancer cell 
growth by being transported inside the cell, converted to DHT, binding to Androgen 
Receptor, and then this complex dimerizes and moves into the nucleus where it acts as 
a transcription factor.  One of the downstream targets that this transcription factor 
regulates is Androgen Receptor itself, allowing for the effect of testosterone to be further 
amplified by increasing the number of available Androgen Receptors for DHT to occupy.  
This positive feedback loop will continually drive the growth and division of these cells. 
(1) 
 
The mechanism of this positive feedback loop is not completely understood, and what is 
understood about it is not intuitive.  When androgen-dependent prostate cancer cells are 
exposed to DHT or synthetic androgens such as R1881, the level of AR mRNA 
decreases, but the mRNA has increased stability and greater protein production 
potential. (7,16-20)  We wanted to determine if you could visualize androgen-induced AR 
mRNA posttranscriptional changes in androgen-dependent prostate cancer cells.  If this 
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was possible, determining if prostate cancer cells exhibit these changes in response to 
hormone stimulation could be used indicate whether or not these cells are still in the 
androgen-dependent phase. 
 
First we conducted a time course of LNCaP exposure to 10 nM R1881 for 48 hours to 
see the temporal response to the hormone in order to determine the time frame when 
the cells are responding to the hormone by downregulating AR mRNA (Figure 28).  
Based on this time course, the cellular response of AR mRNA downregulation appeared 
to occur at 24 hours post-hormone stimulation.  The initial rise in AR mRNA was not 
seen in the literature previously (17), and should be repeated, but the decrease at 24 
hours to about 50% of the control levels has been observed before.  (16-18) 
 
 
Figure 28.  Regulation of AR mRNA expression in LNCaP cells treated with 10 nM 
R1881.  LNCaP cells were exposed to 10 nM R1881 for a period of up to 48 hours.  AR 
mRNA relative expression levels were determined at 0, 6, 24, and 48 hours post-
treatment.  At 6 hours, AR mRNA levels increased, with a sharp decline at 24 hours, and 
recovery towards control levels at 48 hours. 
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Next we wanted to see if there were visible changes in the AR mRNA structure and 
localization that corresponded to this R1881-induced posttranscriptional regulation.  In 
figure 29, you can see that after 24 hours of R1881 exposure, the AR mRNA appears to 
cluster into larger granules.  Whether or not this clustering plays a role in the stabilization 
and increased translational efficiency of this mRNA is yet to be determined. 
 
 
Figure 29.  Visualization of AR mRNA in LNCaP cells treated with 10 nM R1881 for 
24 hours.  LNCaP cells were either 1) not treated or 2) and 3) treated with 10 nM R1881 
for 24 hours.  A) Shows white light and Cy3 fluorescence coregistration to demonstrate 
cellular localization of AR mRNA. B) Shows the fluorescence image alone to clearly 
show the structural changes in AR mRNA.  2B) and 3B) have green dashed lines 
surrounding significantly large mRNA granules that have developed after 24 hours of 
R1881 treatment. 
 
 
4.2 Studying AR mRNA State Changes Associated with the Transition of Prostate 
Cancer from Androgen-Dependent to Androgen-Independent 
 
When a tumor becomes androgen-independent, it no longer requires normal physiologic 
levels of testosterone to continue to grow and divide; it can survive and perpetuate at 
basal hormone levels.  Often this ability to survive in low levels of androgen is due to 
 57 
 
increased levels or optimized distribution of AR protein within the cell so that all available 
testosterone will occupy receptors and form active transcription factors.  
 
Again, AR mRNA’s role in this process is counterintuitive because if you had a tumor 
that could continue to grow in low levels of testosterone, you would assume that AR 
mRNA was upregulated in these tumors to drive the production of AR protein.  However, 
the opposite is the case.  As reported in figure 30, AR mRNA levels in the LNCaP-
derived androgen-independent counterpart cell line, C4-2, is about 50% of that of the 
LNCaP level.  Dr. Peter Leedman’s group believes that differential posttranscriptional 
regulation of AR mRNA in androgen-independent cells drives either the accumulation or 
optimized distribution of AR protein despite the lowered message levels. (7,15,17)  In the 
case of C4-2 cells, their lowered message levels are accompanied by lower AR protein 
levels, so in this case, changes in posttranscriptional regulation that lead to a more 
efficient distribution of the protein within the cell might be at play.  (46) 
 
 
Figure 30.  Differences in AR mRNA expression between LNCaP and C4-2 cells.  
AR mRNA relative expression levels are presented for LNCaP cells and their androgen-
independent counterpart cell line, C4-2.  C4-2 AR mRNA levels are determined to be 
55.87 ±1.34% of that of LNCaP cells. 
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We were curious if AR mRNA posttranscriptional regulation involved in driving the cell 
from the androgen-dependent to the androgen-independent state produced a visible 
change that you could use as a prognostic indicator of when a cell has made that crucial 
transition.  To determine if this was the case, we used our model androgen-dependent 
cell line, LNCaP, and its’ hormone starvation-derived androgen-independent counterpart 
cell line, C4-2, for a head-to-head comparison for determining if differential 
posttranscriptional regulation between the two cell lines caused a visible AR mRNA state 
change.  In figure 31, you can see that the traditional AR mRNA granular pattern in 
LNCaP cells is altered when the cells are transformed to the C4-2 form.  AR mRNA in 
C4-2 cells is granular in structure, but the pattern of the message is more dispersed 
throughout the cytoplasm.  It is unknown whether or not this obvious localization change 
could be used for prognostic purposes. 
 
 
Figure 31.  Visualization of AR mRNA in LNCaP and C4-2 cells.  AR mRNA was 
visualized using the dual chimeric beacon system in 1) LNCaP cells and 2) C4-2 cells.   
A) Shows white light and Cy3 fluorescence coregistration to demonstrate cellular 
localization of AR mRNA. B) Shows the fluorescence image alone to clearly show 
changes in AR mRNA localization.  In 1) LNCaP cells, AR mRNA granules are localized 
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more towards the edges of the cells, in structures we have termed “arms”, while in 2) 
C4-2 cells, AR mRNA granules are dispersed more uniformly throughout the cytoplasm. 
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CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS 
 
 
 
This thesis has presented a method for tracking AR mRNA in live prostate cancer cells 
using dual-labeled hairpin oligonucleotide probes known as molecular beacons.  Two 
potential beacons, AR-7 and AR-24, were designed, tested in solution, and then tested 
in an AR+ prostate cancer cell line, LNCaP, to demonstrate their potential capability of 
allowing for AR mRNA visualization in live cells.   
 
The localization pattern of AR mRNA in AR+ LNCaP cells seen using these AR mRNA 
targeted molecular beacons was interesting in and of itself.  It appears that the message 
localizes predominantly in granules in the extremities or “arms” of the cells.  Localization 
of mRNA to leading edges of a cell has been seen before, further validating this pattern 
as a feasible result.  Dr. Robert Singer’s group observed the same subcellular 
localization for β-actin mRNA in fibroblasts and neurons.  Singer also observed that an 
RNA-binding protein, zipcode binding protein 2 (ZBP2) was required for this localization 
to occur. (42)   It is possible that this clustering of the mRNA in one region of the cell 
enhances mRNA stability or translational efficiency so that more protein can be 
produced.  In the case of AR, this mechanism would allow for high protein accumulation 
that could push the prostate cancer cells to continue to grow and divide in lower levels of 
androgen.   
 
In our discussion of this RNA localization pattern, it is also important to bring up that 
localized RNA granules in mammalian cells are thought to be stress granules, which are 
translationally inactive stores that when locally released can suddenly become 
translationally active to produce a localized rapid burst of protein when the cell is under 
stress.  Perhaps these AR mRNA granules are actually stress granules of stabilized 
 61 
 
mRNA that will become translationally active when needed in order to produce a sudden 
large supply of AR protein.  Co-staining LNCaP and C4-2 cells for translational 
machinery proteins such as eukaryotic translation initiation factor 4G (eIF4G) and 
determining whether or not these proteins colocalize with the AR mRNA granules would 
indicate whether or not these are translationally inactive stress granules.  (47) 
 
The method of AR mRNA detection was optimized through the use of the two beacons in 
tandem and by changing the backbone chemistry of the beacons to a chimeric 
formulation with 2’-O-Me RNA bases in the hybridization domain.  This optimized dual 
chimeric beacon approach allowed for enhancement of the signal-to-background ratio in 
live cell imaging.  The enhanced signal permitted for a decrease in imaging exposure 
time, which allowed for a more dramatic difference in AR mRNA signal between AR+ 
LNCaP cells and AR- DU-145 cells. 
 
The dual chimeric beacon system was validated through a series of tests in order to 
ensure that AR mRNA was being targeted specifically.  Visualizing total RNA in LNCaP 
cells was a strong piece of evidence in this case.  The RNA localization pattern in 
LNCaP cells is granular in nature, matching the structures seen by our beacons.  The 
fact that several mRNAs, including rat AR mRNA, have been shown to localize in 
granules (41,44) coupled with the fact that RNA-binding proteins known to associate with 
AR mRNA have also been shown to localize in granules (43) further encourages our 
results.  The ability of the beacons to distinguish between AR+ LNCaP cells and AR- 
DU-145 cells was another strong piece of evidence supporting the specificity of these 
probes. 
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Many methods for modulating the level of AR mRNA were attempted to add support to 
the validation of our molecular beacon system.  siRNA, Vitamin D treatment, and 
hormone starvation treatment proved to be poor methods for validating our beacons 
either due to the effect of the treatment on cell morphology or the failure of the method to 
cause a significant change in AR mRNA expression that would be visually detectable.   
 
The effects that certain siRNA transfection reagents had on cell morphology were 
disturbing.  While most biologists care simply that they are able to knockdown their 
targeted protein with siRNA, they do not often consider the effects of the reagents 
themselves on cell morphology and function.  The fact that LipofectamineTM 2000 
induced the formation of large vesicles that often became “beacon traps”, unfortunately 
prevented us from using this method as a means for validating our probe system, but 
more importantly it raised the question of what are these transfection reagents really 
doing to our cells.  If such a drastic change in morphology is occurring with reagent 
application, is it fair to say that a non-treated cell is functionally similar to a reagent-
treated cell?  Is the only difference between the two cells the level of the siRNA-targeted 
mRNA and protein, or are there more regulatory changes that are induced by the 
reagent?  These questions remain unanswered and are outside the scope of this thesis, 
but they bring up an important point to be considered by molecular biologists using this 
technique.  As for using siRNA as a method for beacon validation, without the answers 
to those questions, it would be very difficult to definitively use the results of this method 
as proof of beacon specificity, even if they did show the desired result. 
 
Regulation of AR mRNA by thapsigargin, however, proved to be an effective and 
repeatable method for altering AR mRNA levels significantly.  The ability of our beacon 
system to visually track the temporal change in AR mRNA expression due to 
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thapsigargin treatment and post-treatment recovery remains a key piece of evidence 
supporting the specificity of our system.  
  
However, the fluorescence quantification of this treatment regimen did not produce as 
convincing results as the visualization itself.  Fluorescence quantification was performed 
on deconvolved Z-stacks of 0.2 µm thick slices of cultured cells using the softWoRx 
image analysis package.  Despite the obvious visual differences between time points in 
the thapsigargin treatment and recovery time course, when quantifying the fluorescence 
levels of the cells using this quantification method, minimal differences were observed.  
A reason for this could be that the contribution of the beacon fluorescence to the overall 
fluorescence in the cell is minimal due to a high level of background fluorescence picked 
up by the quantification system.  When the average fluorescence per 1 µm3 volume was 
calculated for areas on the glass slide without cells on it and this value was compared to 
the average fluorescence per 1 µm3 cellular volume of non-treated LNCaP cells, it was 
found that the glass slide had an average of 78.91% of the fluorescence signal seen in 
non-treated cells.  This means that a staggering amount of the fluorescence picked up 
could be due to non-beacon signal.  The method for quantifying intracellular 
fluorescence levels needs to be examined further in order to remove noise that could be 
overshadowing actual differences in beacon fluorescence between cellular treatment 
groups.  This raises questions concerning the best way to normalize the quantified 
cellular fluorescence by subtracting out background.  Would it be appropriate to use the 
blank glass slide fluorescence for normalization, or would a cell without beacons in it be 
more appropriate, or would a dark area within a cell be the right choice?  Using the glass 
slide seems the most straightforward, but does cell adherence to the slide change the 
amount of fluorescence emitted from the slide itself?  Cells without beacons might have 
a different level and distribution of autofluorescence than cells containing beacons.  
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Selecting a dark area within a cell would be subjective and it would be difficult to ensure 
consistency from experiment to experiment and user to user.   Further exploration of this 
topic needs to occur in order to improve this method of fluorescence quantification 
enough to make it a viable tool in helping to prove probe specificity. 
 
Once the AR mRNA dual chimeric beacon system had undergone several validation 
tests, we then determined that this system could be utilized to study posttranscriptional 
regulation of AR mRNA in prostate cancer cells.  We were able to detect changes in AR 
mRNA state when LNCaP cells were stimulated with the synthetic androgen, R1881.  
After 24 hours of hormone stimulation, AR mRNA accumulated in large granules.   It is 
not known at the present time whether there is functional relevance to this AR mRNA 
accumulation.  Since hormone stimulation of LNCaP cells is known to lead to increased 
production of AR protein, which in turn pushes the cells to continue to grow and divide, 
we speculate that this reorganization of AR mRNA into large clustered granules is to add 
to message stability and/or translational efficiency of the message, both of which would 
lead to increased protein production.  It is uncertain at this time whether or not you could 
prove the reorganization of the AR mRNA in response to hormone stimulation 
contributes to this mechanism. 
 
It would be interesting to take this hormone stimulation experiment one step further and 
see how the structure and localization of AR mRNA changes at time points between 0 
and 24 hours.  Once seeing how AR mRNA is regulated in LNCaP cells during this 
dramatic period of hormone stimulation, it would be interesting to switch to the 
androgen-independent C4-2 model cell line and see how it’s regulation of AR mRNA 
differs during hormone stimulation.  Since C4-2 cells are in the androgen-independent 
phase, would they respond to the hormone at all or would the changes be considerably 
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less dramatic?  The answer to this is unsure, but if there is a differential response, 
perhaps the alteration in response could be used as a prognostic indicator for 
determining whether AR+ prostate cancer cells are in the androgen-dependent or 
androgen-independent state.  It would first be necessary to determine if these 
localization patterns and changes are characteristic of other AR+ prostate cancer cells, 
not just LNCaP and C4-2 model cell lines.  You could potentially determine whether this 
AR mRNA localization pattern and distribution change occurs in other cases of AR+ 
prostate cancer by visualizing the AR mRNA localization in AR+ prostate cancer cells 
that have already been characterized as androgen-dependent or androgen-independent 
and determining if they follow the trend of these model cell lines.   
 
The AR mRNA detection system was also useful in showing differences in AR mRNA 
localization between the androgen-dependent LNCaP cells and their androgen-
independent counterpart cell line, C4-2.   β-actin mRNA spatial localization seen in 
fibroblasts and neurons (41,42) has been shown to serve the purpose of providing a 
localized concentration of β-actin protein in these cells. (48,49)  If these AR mRNA 
granules are truly stress granules, perhaps the alteration in localization between LNCaP 
and C4-2 cells is due to the need for rapid large bursts of AR protein more 
homogenously in C4-2 cells in order to enable these cells to survive in low androgen 
levels.  By having a more dispersed production of AR, the likelihood of AR encountering 
DHT in these cells should increase, helping push the AR growth pathway. 
 
It has not been shown at this time whether or not these changes in AR mRNA structure 
and localization occur in other AR+ prostate cancer cells, besides LNCaP cells, as they 
transition from androgen-dependent to androgen-independent.  If this was shown to be a 
common phenomenon, determining AR mRNA localization could prove to be a useful 
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prognostic indicator of when prostate cancer is in the androgen-dependent or androgen-
independent phase.  Again, it would be necessary to look at AR mRNA localization and 
distribution changes in other AR+ prostate cancer cells to see if this trend is not just a 
phenomenon of the LNCaP and C4-2 cell lines.   
 
Future experiments can also be conducted to show how this change in AR mRNA 
organization occurs over the course of the transition between androgen-dependence to 
androgen-independence.  LNCaP cells can be transformed into androgen-independent 
C4-2 cells by repeated hormone starvation over a period of several months (50) or some 
researchers have shown it can be done through the upregulation of certain factors, such 
as Protein Kinase Cε, in a much shorter time frame, on the order of a week. (51)  
Visualizing changes in AR mRNA localization over this important transition could allow 
one to not only make the black-or-white call between an androgen-dependent or 
androgen-independent diagnosis, but allow for the determination of whether the cancer 
cells are in the process of making that critical transition.   
 
Our collaborators at Emory University, as well as others, are interested in the role that 
prostate tumor stroma plays is the progression and regulation of prostate cancer cells. 
(52)   It has already been shown that the co-culture of tumor and stromal cells can have 
a profound impact on the population of stromal cell mRNA interacting with a specific 
RNA-binding protein.  Dr. Jack Keene’s group co-cultured PY4.1 endothelial cells with 
4T1 breast cancer cells and found that the subpopulation of mRNA interacting with 
poly(A) binding protein (PABP) in the co-cultured stromal cells differed from those in the 
stromal cells cultured independently.  PABP-interacting mRNAs that were upregulated in 
response to the tumor cells included Cyclins, proliferation factors, and transcription 
factors. (53)  Since cancer cells can have a profound impact on mRNA regulation in 
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stromal cells, it is logical that the inverse would be true as well.  It would be of interest to 
co-culture both LNCaP and C4-2 prostate cancer cell lines with stromal cells to see if the 
posttranscriptional regulation of AR mRNA changes.  Repeating the hormone stimulation 
experiments in the presence of stromal cells and seeing how the prostate cancer cells 
respond in their regulation of AR mRNA could provide insight into the importance of 
stromal cell interactions in these regulatory mechanisms.   
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